Regulations.gov document
NDI 1259 - Reinstatement Response Letter from FDA HFP to Inner Mongolia Kingdomway…
Other · FDA-2022-S-0023 · posted Dec 9, 2025
Key facts
| Document ID | FDA-2022-S-0023-0069 |
|---|---|
| Title | NDI 1259 - Reinstatement Response Letter from FDA HFP to Inner Mongolia Kingdomway Pharmaceutical Limited regarding NDI 1259 - B-Nicotinamide Mononucleotide (NMN) |
| Document type | Other |
| Subtype | 75 Day PreMarket Notification |
| Agency | FDA |
| Docket | FDA-2022-S-0023 |
| Posted | Dec 9, 2025 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: